Recent Research Analysts’ Ratings Changes for Hims & Hers Health (HIMS)

Hims & Hers Health (NYSE: HIMS) has recently received a number of price target changes and ratings updates:

• 3/16/2026 – Hims & Hers Health had its price target raised by Leerink Partners from $17.50 to $25.00. They now have a “market perform” rating on the stock.
• 3/11/2026 – Hims & Hers Health had its price target raised by Barclays PLC from $25.00 to $29.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Hims & Hers Health was upgraded by Citigroup Inc. from “sell” to “neutral”. They now have a $24.00 price target on the stock, up from $13.25.
• 3/10/2026 – Hims & Hers Health was upgraded by Bank of America Corporation from “underperform” to “neutral”. They now have a $23.00 price target on the stock, up from $12.50.
• 3/10/2026 – Hims & Hers Health had its price target raised by Deutsche Bank Aktiengesellschaft from $25.00 to $28.00. They now have a “hold” rating on the stock.
• 3/9/2026 – Hims & Hers Health was upgraded by Needham & Company LLC from “hold” to “buy”. They now have a $30.00 price target on the stock.
• 2/25/2026 – Hims & Hers Health was upgraded by Zacks Research from “strong sell” to “hold”.
• 2/24/2026 – Hims & Hers Health had its price target lowered by Barclays PLC from $48.00 to $25.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Hims & Hers Health had its price target lowered by TD Cowen from $20.00 to $17.00. They now have a “hold” rating on the stock.
• 2/24/2026 – Hims & Hers Health had its price target lowered by Morgan Stanley from $40.00 to $21.00. They now have an “equal weight” rating on the stock.
• 2/24/2026 – Hims & Hers Health was given a new $24.00 price target by Evercore Inc.
• 2/24/2026 – Hims & Hers Health had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $18.00 price target on the stock, down from $37.00.
• 2/24/2026 – Hims & Hers Health had its price target lowered by Leerink Partners from $20.00 to $17.50. They now have a “market perform” rating on the stock.
• 2/24/2026 – Hims & Hers Health had its price target lowered by Citigroup Inc. from $16.50 to $13.25. They now have a “sell” rating on the stock.
• 2/24/2026 – Hims & Hers Health was downgraded by BTIG Research from “buy” to “neutral”.
• 2/10/2026 – Hims & Hers Health was given a new $31.00 price target by Deutsche Bank Aktiengesellschaft. They now have a “hold” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by TD Cowen from $30.00 to $20.00. They now have a “hold” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by Citigroup Inc. from $30.00 to $16.50. They now have a “sell” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by Bank of America Corporation from $26.00 to $21.00. They now have an “underperform” rating on the stock.
• 2/2/2026 – Hims & Hers Health had its price target lowered by BTIG Research from $85.00 to $60.00. They now have a “buy” rating on the stock.
• 1/19/2026 – Hims & Hers Health was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at approximately $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 80,463 shares of company stock valued at $2,846,696 in the last ninety days. 17.71% of the stock is owned by insiders.

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.